SYSTEMI - Systemic organ communication in STEMI: Design and rationale of a cohort study of patients with ST-segment elevation myocardial infarction

F Bönner; C Jung; A Polzin; R Erkens; L Dannenberg; R Ipek; M Kaldirim; M Cramer; P Wischmann; O-P Zaharia; C Meyer; U Flögel; B Levkau; A Gödecke; JW Fischer; N Klöcker; M Krüger; M Roden; M Kelm

doi:10.1101/2023.01.13.23284541

Abstract

Background (335/350) ST-segment elevation myocardial infarction (STEMI) still causes significant mortality and morbidity despite best-practice revascularization and adjunct medical strategies. Within the STEMI population, there is a spectrum of higher and lower risk patients with respect to major adverse cardiovascular and cerebral events (MACCE) or re-hospitalization due to heart failure. Myocardial and systemic metabolic disorders modulate patient risk in STEMI. Systematic cardiocirculatory and metabolic phenotyping to assess the bidirectional interaction of cardiac and systemic metabolism in myocardial ischemia is lacking.

Methods Systemic organ communication in STEMI (SYSTEMI) is an all-comer open-end prospective study in STEMI patients >18 years of age to assess the interaction of cardiac and systemic metabolism in STEMI by systematically collecting data on a regional and systemic level. Primary endpoint will be myocardial function, left ventricular remodelling, myocardial texture and coronary patency at 6 month after STEMI. Secondary endpoint will be all-cause death, MACCE, and re-hospitalisation due to heart failure or revascularisation assessed 12 month after STEMI. The objective of SYSTEMI is to identify metabolic systemic and myocardial master switches that determine primary and secondary endpoints. In SYSTEMI 150-200 patients are expected to be recruited per year. Patient data will be collected at the index event, within 24 hours, 5 days as well as 6 and 12 months after STEMI. Data acquisition will be performed in multilayer approaches. Myocardial function will be assessed by using serial cardiac imaging with cineventriculography, echocardiography and cardiovascular magnetic resonance. Myocardial metabolism will be analysed by multi-nuclei magnetic resonance spectroscopy. Systemic metabolism will be approached by serial liquid biopsies and analysed with respect to glucose and lipid metabolism as well as oxygen transport. In summary, SYSTEMI enables a comprehensive data analysis on the levels of organ structure and function alongside hemodynamic, genomic and transcriptomic information to assess cardiac and systemic metabolism.

Discussion SYSTEMI aims to identify novel metabolic patterns and master-switches in the interaction of cardiac and systemic metabolism to improve diagnostic and therapeutic algorithms in myocardial ischemia for patient-risk assessment and tailored therapy.

Trial registration Trial Registration Number: NCT03539133; Registration Date 29.05.2018

Administrative information Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/).

Funding {4}This trial was supported by the German Research Foundation SFB 1116 Grant No. 236177352, as well as project grants BO 4264/1-1 (F.B.); the German Diabetes Center (DDZ), which is funded by the German Federal Ministry of Health and the Ministry of Culture and Science of the state North Rhine-Westphalia and from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD).

Trials structured Study Protocol template Trials guidance: the numbers in curly brackets (e.g. {5a}) are SPIRIT item identifiers. Please do not remove the numbers in curly brackets, or any heading that contains them. The item identifiers are slightly out of sequence to make the document flow more easily but it is important that they remain in the document to allow electronic searches by SPIRIT item number. https://trialsjournal.biomedcentral.com/submission-guidelines/preparing-your-manuscript/study-protocoll

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT03539133

Funding Statement

This trial was supported by the German Research Foundation SFB 1116 Grant No. 236177352, as well as project grants BO 4264/1-1 (F.B.); the German Diabetes Center (DDZ), which is funded by the German Federal Ministry of Health and the Ministry of Culture and Science of the state North Rhine-Westphalia and from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ethics committees of Heinrich-Heine-University Duesseldorf Germany and State Medical Association North Rhine (Landesaerztekammer Nordrhein) Germany gave ethical approval for this work complying with the Declaration of Helsinki

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Name and contact information for the trial sponsor {5b}, Heinrich-Heine University.
Role of sponsor {5c}, Heinrich Heine University

Data Availability

All data produced in the present work are contained in the manuscript

Abbreviations

AI: = Artificial intelligence
CEST: = Chemical exchange saturation transfer
CS: = Cardiogenic shock
CKD: = Chronic kidney disease
CMR: = Cardiac magnetic resonance
CRC: = Collaborative Research Consortium
DMC: = Data Monitoring Committee
DOSAR: = Düsseldorf outcome and safety registry
EAC: = Endpoint Adjunction Committee
EF: = Ejection fraction
ECV: = Extracellular volume fraction
EDV: = End-diastolic volume
ESV: = End-systolic volume
FMD: = Flow-mediated dilatation
FU: = Follow-up
HbA1c: = Hemoglobin A1c
HOMA: = Homeostasis model assessment I
MH: = Intramyocardial hemorrhage
ID: = Iron deficiency
IS: = Infarct size
LAS: = Large artery stiffness
LDL-C: = Low-density lipoprotein cholesterol
LV: = Left ventricle
MACEs: = Major adverse cardiovascular events
MRS: = Magnetic resonance spectroscopy
MVO: = Microvascular obstruction
6MWT: = 6 minutes walk test
NAFLD: = Non-alcoholic fatty liver disease
OGTT: = Oral glucose tolerance test
pPCI: = Primary percutaneous coronary intervention
PWV: = Pulse wave velocity
SMuRF: = Standard modifiable cardiovascular risk factor
SOP: = Standard operating procedure
STEMI: = ST-segment elevation myocardial infarction
SV: = Stroke volume
SYSTEMI: = Systemic organ communication in STEMI
TMC: = Trial Management Committee
T2DM: = Type 2 diabetes mellitus

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.